Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1367 | Gam-COVID-Vac Lyo Wiki | 1.00 |
drug1366 | Gam-COVID-Vac Wiki | 0.38 |
drug2490 | Placebo Wiki | 0.13 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.
Description: For Phase II study - - Incidence & severity of adverse events (AEs) after first dose of IMP/Placebo For Phase III study - - Incidence of related serious adverse events (SAEs) following vaccination during the study
Measure: Adverse Events Time: For Phase II study - at Day 28; For Phase III study - till day 180 after first doseDescription: For Phase II study - - Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group
Measure: Immunogenicity Time: For Phase II study - Day 28 after first doseDescription: For Phase III study - Geometric mean titre ratio of SARS-CoV-2 glycoprotein-specific antibodies between IMP and placebo in immunogenicity group
Measure: Immunogenicity Time: For Phase III study - Day 42 after first doseDescription: Incidence and severity of adverse events after injecting the first dose of the IMP/placebo Incidence of SAE following vaccination
Measure: Adverse Events Time: Baseline to Day 180Description: Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group Seroconversion rate of SARS-CoV-2 virus-neutralizing antibodies in immunogenicity group
Measure: Immunogenicity assessment Time: Baseline, Day 21, Day 28, Day 42, Day 90, and Day 180Description: Geometric mean virus-neutralizing antibodies titre in immunogenicity group
Measure: Immunogenicity assessment Time: Baseline, Day 21, Day 28, Day 42, Day 90, and Day 180Description: Interferon gamma concentration in T-cells after restimulation with the SARS-CoV-2 glycoprotein in cell mediated immunogenicity group
Measure: Immunogenicity assessment Time: Baseline, Day 28, Day 42, Day 90 and Day 180Description: The number of proliferating cluster of differentiation 4 (CD4) cell and cluster of differentiation 8 (CD8) cells in response to mitogen stimulation in cell mediated immunogenicity group
Measure: Immunogenicity assessment Time: Baseline, Day 28, Day 42, Day 90 and Day 180Description: Comparing percentage of subjects developing COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo based on severity course
Measure: Percentage of subjects with mild, moderate, severe coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose of the vaccine/placebo Time: Baseline to Day 180Description: Comparing incidence of COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo
Measure: Incidence of coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose in trial subjects Time: Baseline to Day 180Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports